Sponsor content
71 result(s) found, displaying 61 to 70
-
Prescription medicine decision summaryTGA Decision: Yuflyma (adalimumab) is approved to treat multiple auto-immune conditions.
-
Prescription medicine registrationActive ingredients: adalimumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HERZUMA trastuzumab (rch) 440 mg powder for injection for intravenous infusion vial with diluent.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Regdanvimab
-
Prescription medicine registrationActive ingredients: regdanvimab.
-
Designation or determinationProvisional approval
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HERZUMA trastuzumab (rch) 150 mg powder for injection for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRUXIMA rituximab (rch) 100 mg/ 10 mL concentrate solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRUXIMA rituximab (rch) 500 mg/ 50 mL concentrate solution for intravenous infusion.
-
Australian public assessment report (AusPar)Australian Public Assessment for Rituximab